SUPPLY CHAIN MANAGEMENT PART 1: GETTING IT RIGHT FROM THE START
The manufacture, delivery and administration of advanced therapies (cell-, tissue- and gene-based treatments) comprise a sensitive chain of custody that may be thought of as an integrated service system. The system is challenging to assemble for the predominantly small businesses that seek to compete in this sector. The current investment climate is not favorable to proposals unless they have a high probability of success or are capital-efficient or both. Business models based around the extended enterprise, the collaborative enterprise and the franchise models are relatively under-explored for the sector. This paper sets out the main characteristics of these models and the reasons that they may increase the pace of innovation: by reducing investment burden, by encouraging co-ownership of the chain of custody and by allowing early data capture to assist with investment proposals.
Submitted for peer review: Dec 15 2017 Published: Apr 5 2018
Citation: Cell Gene Therapy Insights 2018; 4(3), 157-172.